Previous 10 | Next 10 |
BioXcel Therapeutics ( NASDAQ: BTAI ) is scheduled to announce Q2 earnings results on Monday, August 9th, before market close. The consensus EPS Estimate is -$1.18 (-6.3% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 ...
Major earnings expected before the bell on Tuesday include: Bausch Health Companies ( BHC ) Cronos Group ( CRON ) Emerson Electric ( EMR ) Norwegian Cruise Line Holdings ( NCLH ) Workhorse Group ( WKHS ) For further details see: Notable ea...
NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta,...
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment Over 142 million opioid prescriptions dispensed in the U.S. in 2020 1 More than 1.7 million people in the U.S. suffered from subst...
NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will rele...
BioXcel is currently conducting phase II and III trials of BXCL501 to treat acute agitation in patients with dementia and Alzheimer's. The results of phase II are expected very soon (July or August), and the results of phase III for the end of this year 2022. The annual revenue po...
It's not difficult to find companies that have recently performed poorly on the market. After all, equities are experiencing a downturn, and the S&P 500 is in a full-blown bear market (defined as a 20% or more drop from its most recent highs). History suggests that stocks will event...
Neuroscience and immuno-oncology drugs specialist BioXcel Therapeutics (NASDAQ: BTAI) was a stock on the move this week. Happily, that direction of movement was upwards, as according to data provided by S&P Global Market Intelligence the shares gained nearly 14% this week. A...
Biopharmaceutical companies Athira Pharma ( ATHA ) and BioXcel Therapeutics ( BTAI ) have outperformed the gains in the biotech space on Thursday after Mizuho launched their coverage on small and mid-cap names focused on the central nervous system (CNS). Despite being a high...
NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment o...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...